Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis

Kabaçam, Gökhan; Dalekos, George Ν.; Çakalǒglu, Yılmaz; Zachou, Kalliopi; Bock, C.‐Thomas; Erhardt, Andreas; Zeuzem, Stefan; Tabak, Fehmı; Yalçın, Kendal; Bozdayı, A. Mithat; Dienes, Hans Peter; Bozkaya, Hakan; Manns, Michael P.; Wedemeyer, Heiner; Yurdaydın, Cihan

doi:10.4318/tjg.2012.0538

Cited by 22 publications

(16 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5 Waiting for novel therapies, 6 peginterferon alfa remains the best option 7 , albeit its efficacy is limited 8 and there is no consensus about its duration. 9 Our experience strengthens the idea of very prolonged treatment with peginterferon alfa in selected patients, that is, those able to tolerate the therapy, even those with advanced compensated liver disease, 10 and when close monitoring of biochemical and virological parameters is feasible.…”

supporting

confidence: 57%

Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa - authors' reply

Koh

Heller

2015

Aliment Pharmacol Ther

View full text Add to dashboard Cite

supporting

confidence: 57%

Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa - authors' reply

Koh

Heller

2015

Aliment Pharmacol Ther

View full text Add to dashboard Cite

“…Extending the duration of Peg-IFN therapy has shown no effect on response rate [49]. In a study from Turkey, 32 % of patients with advanced chronic liver disease achieved virological response with Peg-IFN treatment and there was no significant difference in treatment response between patients with advanced and non-advanced chronic liver disease [50]. Acute HDV hepatitis has been more challenging to treat.…”

Section: Treatmentmentioning

confidence: 99%

Hepatitis Delta: Epidemiology, Diagnosis and Management 36 Years After Discovery

Noureddin

Gish

2013

Curr Gastroenterol Rep

View full text Add to dashboard Cite

With recent studies showing increased prevalence of hepatitis delta (HDV) even in the US, Australia, and some countries in Europe, and very high prevalence in endemic regions, HDV infection is far from being a disappearing disease. Although immigrants from endemic countries have been shown to have increased risk, studies have clearly shown that the disease is not solely appearing in traditional high-risk groups. Recent studies provide increasing evidence that sexual transmission may be an important factor in HDV infection spread. Based on the totality of evidence showing increased disease progression and substantially increased risk of cirrhosis in HDV-infected CHB patients, and the current studies showing higher than expected prevalence, it is time to call for HDV screening of all CHB patients. HDV viral load detection and measurement should be considered in all patients whether or not they are anti-HDV-positive. With universal screening of CHB patients for HDV, earlier diagnosis and consideration of treatment would be possible. Current treatment of HDV is IFN-based therapy with or without HBV antivirals, but current research indicates the possibility that prenylation inhibitors, entry inhibitors, HBsAg release inhibitors, or other therapies currently in the pipeline may provide more effective therapy in the future. In addition, universal screening would serve the important public health goal of allowing patients to be educated on their status and on the need for HDV-negative patients to protect themselves against superinfection and for HDV-infected patients to protect against transmission to others. Further studies and global awareness of HDV infection are needed.

show abstract

“…Although some studies reported that interferon treatment can be safely used in patients with compensated cirrhosis (38), decompensation might develop during the treatment.…”

Section: Contraindications Side Effects and Monitorization Of Pegifnmentioning

confidence: 99%

Diagnosis, management and treatment of hepatitis delta virus infection: Turkey 2017 Clinical Practice Guidelines

Yurdaydın

Tabak

Kaymakoğlu

et al. 2017

Turk J Gastroenterol

Self Cite

View full text Add to dashboard Cite

Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis

Cited by 22 publications

References 33 publications

Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa - authors' reply

Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa - authors' reply

Hepatitis Delta: Epidemiology, Diagnosis and Management 36 Years After Discovery

Diagnosis, management and treatment of hepatitis delta virus infection: Turkey 2017 Clinical Practice Guidelines

Contact Info

Product

Resources

About